HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
HOOKIPA Pharma (NASDAQ: HOOK) announced its participation in the virtual investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit on December 6-7, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HOOKIPA Pharma (NASDAQ: HOOK) announced its participation in the virtual investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit on December 6-7, 2022. The company focuses on developing novel immunotherapies using its proprietary arenavirus platform, which aims to mobilize targeted T cells against serious diseases. HOOKIPA’s pipeline includes investigational treatments for Human Papillomavirus 16-positive cancers, prostate cancers, and collaborations with Roche and Gilead for KRAS-mutated cancers and functional cures for HBV and HIV, respectively.
Details
News Market Reaction – HOOK
The recorded move for HOOK in the trading session of this news was +1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 - 7, 2022.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media | Investors | |
| Instinctif Partners | Matt Beck | |
| hookipa@instinctif.com | Executive Director - Investor Relations | |
| +44 (0)20 7457 2020 | matthew.beck@hookipapharma.com | |
| +1 917 209 6886 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.